Sign in
CATB Stock Price, Chart, Stats & News
Catabasis Pharmaceuticals, Inc.
Save
234.86M
Market cap
–
Current P/E
–
Forward P/E
CATB chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | -15144.33% |
Pretax margin | -13938.24% |
Net margin | -13938.24% |
Effective tax rate | – |
ROA | -36.20% |
ROE | -35.71% |
D/E | 0.02x |
Interest coverage ratio | – |
CATB valuation
P/E | – |
P/S | 332.66x |
P/B | – |
P/CF | – |
P/FCF | -2.28x |
P/OCF | – |
PEG | – |
EV multiple | -3.13x |
About
Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic treatments primarily within the United States. Their leading experimental drug, edasalonexent, is an oral small molecule undergoing Phase III clinical trials for Duchenne Muscular Dystrophy (DMD), functioning by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells. Additionally, the company is developing CAT-5571 as a potential treatment for cystic fibrosis.
Similar securities
Based on sector and market capitalization
Report issue